Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer
- 15 April 1979
- journal article
- research article
- Published by Elsevier in European Journal of Cancer (1965)
- Vol. 15 (4), 593-601
- https://doi.org/10.1016/0014-2964(79)90097-5
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- PROGESTAGENS AND ADVANCED BREAST CANCERThe Lancet, 1971
- Clinical trial of Δ1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer:A report of the cooperative breast cancer groupCancer, 1969
- Treatment of Breast Cancer with Medroxyprogesterone AcetateAnnals of Internal Medicine, 1968
- Hormonal therapy in cancer of the breast.XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretionCancer, 1967
- Progestin therapy of breast cancer: comparison of agents.BMJ, 1967
- Clinical trial of delalutin in the treatment of advanced mammary carcinoma in postmenopausal womenCancer, 1962
- Hormonal therapy in carcinoma of the breast.I. Effect of oral progesterone on clinical course and metabolism of nitrogen and selected electrolytes and steroidsCancer, 1960
- Hormonal therapy of metastatic female breast carcinoma.I. 9α-bromo-11-ketoprogesteroneCancer, 1959
- Clinical and pharmacological observations of the effects of 9-α-bromo-11-β-ketoprogesterone in patients with carcinoma of the breastCancer, 1959
- Hormonal therapy in cancer of the breast.III. Effect of progesterone on clinical course and hormonal excretionCancer, 1952